These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 21337704)

  • 21. Review of a current role of mass spectrometry for proteome research.
    Chen CH
    Anal Chim Acta; 2008 Aug; 624(1):16-36. PubMed ID: 18706308
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mass spectrometry is only one piece of the puzzle in clinical proteomics.
    McGuire JN; Overgaard J; Pociot F
    Brief Funct Genomic Proteomic; 2008 Jan; 7(1):74-83. PubMed ID: 18308835
    [TBL] [Abstract][Full Text] [Related]  

  • 23. CE-MS in biomarker discovery, validation, and clinical application.
    Mischak H; Schanstra JP
    Proteomics Clin Appl; 2011 Feb; 5(1-2):9-23. PubMed ID: 21280234
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Label-free mass spectrometry-based protein quantification technologies in proteomic analysis.
    Wang M; You J; Bemis KG; Tegeler TJ; Brown DP
    Brief Funct Genomic Proteomic; 2008 Sep; 7(5):329-39. PubMed ID: 18579615
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Recent advances in capillary electrophoresis-based proteomic techniques for biomarker discovery.
    Fang X; Balgley BM; Lee CS
    Electrophoresis; 2009 Dec; 30(23):3998-4007. PubMed ID: 19960464
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Introducing the CPL/MUW proteome database: interpretation of human liver and liver cancer proteome profiles by referring to isolated primary cells.
    Wimmer H; Gundacker NC; Griss J; Haudek VJ; Stättner S; Mohr T; Zwickl H; Paulitschke V; Baron DM; Trittner W; Kubicek M; Bayer E; Slany A; Gerner C
    Electrophoresis; 2009 Jun; 30(12):2076-89. PubMed ID: 19582709
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mass spectrometry-based clinical proteomics: head-and-neck cancer biomarkers and drug-targets discovery.
    Matta A; Ralhan R; DeSouza LV; Siu KW
    Mass Spectrom Rev; 2010; 29(6):945-61. PubMed ID: 20945361
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Lucid Proteomics System for top-down biomarker research.
    Jourdain S; Bulman A; Dalmasso E
    Arch Physiol Biochem; 2010; 116(4-5):158-62. PubMed ID: 20507259
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Application of proteomic technologies for prostate cancer detection, prognosis, and tailored therapy.
    Fredolini C; Liotta LA; Petricoin EF
    Crit Rev Clin Lab Sci; 2010; 47(3):125-38. PubMed ID: 20858067
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Approaches to dimensionality reduction in proteomic biomarker studies.
    Hilario M; Kalousis A
    Brief Bioinform; 2008 Mar; 9(2):102-18. PubMed ID: 18310106
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Quantify this! Report on a round table discussion on quantitative mass spectrometry in proteomics.
    Quadroni M; Ducret A; Stöcklin R
    Proteomics; 2004 Aug; 4(8):2211-5. PubMed ID: 15274113
    [TBL] [Abstract][Full Text] [Related]  

  • 32. High-performance proteomics as a tool in biomarker discovery.
    Meyer HE; Stühler K
    Proteomics; 2007 Sep; 7 Suppl 1():18-26. PubMed ID: 17893859
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Recent advances in atherosclerosis-based proteomics: new biomarkers and a future perspective.
    Alvarez-Llamas G; de la Cuesta F; Barderas ME; Darde V; Padial LR; Vivanco F
    Expert Rev Proteomics; 2008 Oct; 5(5):679-91. PubMed ID: 18937558
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Plasma-derived microparticles for biomarker discovery.
    Smalley DM; Ley K
    Clin Lab; 2008; 54(3-4):67-79. PubMed ID: 18630736
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Data management and functional annotation of the Korean reference plasma proteome.
    Jeong SK; Lee EY; Cho JY; Lee HJ; Jeong AS; Cho SY; Paik YK
    Proteomics; 2010 Mar; 10(6):1250-5. PubMed ID: 20175082
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Morphinome--a meta-analysis applied to proteomics studies in morphine dependence.
    Bodzon-Kułakowska A; Kułakowski K; Drabik A; Moszczynski A; Silberring J; Suder P
    Proteomics; 2011 Jan; 11(1):5-21. PubMed ID: 21182190
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Industrialized MS-based proteomics in the search for circulating biomarkers.
    Migneault I; Hunter JM
    Bioanalysis; 2009 Sep; 1(6):1149-63. PubMed ID: 21083081
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mass spectrometry-coupled techniques for viral-related disease biomarker identification.
    Rhea JM; Diwan CA; Molinaro RJ
    Biomark Med; 2010 Dec; 4(6):859-70. PubMed ID: 21133707
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Application of an end-to-end biomarker discovery platform to identify target engagement markers in cerebrospinal fluid by high resolution differential mass spectrometry.
    Paweletz CP; Wiener MC; Bondarenko AY; Yates NA; Song Q; Liaw A; Lee AY; Hunt BT; Henle ES; Meng F; Sleph HF; Holahan M; Sankaranarayanan S; Simon AJ; Settlage RE; Sachs JR; Shearman M; Sachs AB; Cook JJ; Hendrickson RC
    J Proteome Res; 2010 Mar; 9(3):1392-401. PubMed ID: 20095649
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Data processing pipelines for comprehensive profiling of proteomics samples by label-free LC-MS for biomarker discovery.
    Christin C; Bischoff R; Horvatovich P
    Talanta; 2011 Jan; 83(4):1209-24. PubMed ID: 21215856
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.